Androlabs, the men’s health pharmaceutical company, announces that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for Testavan® 4.6 mg/actuation Transdermal Gel on 5 May 2026.
Testavan® 4.6 mg/actuationTransdermal Gel is indicated as testosterone replacement therapy in adult men with hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
The marketing authorisationis held by The Simple Pharma Company UK Limited under licence number PL54460/0004. Testavan® will be promoted in the UK by Androlabs. Both companies are part of the Tithonia Group.
The authorisation adds a new Testavan presentation to Androlabs’ UK portfolio and reflects the company’s commitment to supporting healthcare professionals involved in the management of adult male hypogonadism.
Healthcare Professionals should refer to the UK Summary of Product Characteristics for full prescribing information before prescribing Testavan®.
Testavan® 4.6 mg/actuation Transdermal Gel is classified as a Prescription Only Medicine (POM) in the UK. This announcement concerns the granting of the marketing authorisation. Commercial launch timing and product availability will be communicated separately.
Suspected adverse reactions should be reported through the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk